Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Epistaxis: early-phase trial registry

1 of 5 indexed Epistaxis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Epistaxis: 5 US clinical trials tracked, 1 recruiting.

Epistaxis is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Cure HHT, running 2 of these trials.

Enrollment posture brief

Registry condition epistaxis

OPEN 1 | RECR 20% | LATE 0 | EARLY 2 | RANK #3391 | SPON 2

Volume-matched condition peers

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Epistaxis (this)20%
Open-enrollment share among volume-matched conditions near Epistaxis

Epistaxis lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Epistaxis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Epistaxis is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Epistaxis research.

    Cure HHT accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Epistaxis trials plan to enrol fewer than 100 people.

    Median target enrolment is 70 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Epistaxis research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Top Sponsors

Cure HHT 2 trials
Lisa Shnayder 1 trials
Nemours Children's Clinic 1 trials
University of Minnesota 1 trials

Named interventions

Most-linked intervention names on Epistaxis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Sclerotherapy Drug
1 trials
Standard nasotracheal tube Device
1 trials
Parker flex-tip nasotracheal tube Device
1 trials
Saline mixture Other
1 trials
Pazopanib Drug
1 trials
Placebo oral capsule Drug
1 trials
Standard Treatment Other
1 trials

US sites by state

Facility locations filed on Epistaxis trials. A trial with sites in several states counts in each.

Minnesota 3 trials
Utah 2 trials
Texas 2 trials
Ohio 2 trials
North Carolina 2 trials
Missouri 2 trials
Massachusetts 2 trials
Georgia 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Epistaxis page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Epistaxis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Cure HHT sponsors the most Epistaxis trials on record, review their full trial history before evaluating a specific study. See Cure HHT's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Epistaxis condition card totals 5 registered trials; most-linked intervention Sclerotherapy; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.